How Global Price Controls and Policy Shifts Are Rewiring Biopharma

EMERYVILLE, Calif. – November 12, 2026 — The global biopharmaceutical industry is undergoing a seismic realignment. For decades, the unwritten social contract of medical innovation relied on a delicate, often contentious balance: high prices in the United States subsidized the immense risks of global research and development, while other wealthy nations utilized strict price controls to manage their sovereign healthcare budgets.

Today, that paradigm is fracturing.

A new collection of 18 working papers released by the Eira Initiative, an applied policy research project associated with the Berkeley Policy Institute, lays bare the profound ways in which recent regulatory shifts, tax policies, and price controls are rewiring the geography and focus of medical innovation. Originally presented at the "Competing for the Cure" conference in Paris, the research provides a stark, data-driven look at the trade-offs policymakers are making—often inadvertently—as they attempt to rein in healthcare costs.

"Across the globe, policymakers face difficult questions about how to improve access to medicines while sustaining the research that produces new treatments," said Bowman Heiden, co-director of the Eira Initiative. "Answering those questions requires evidence about how policies work in practice. Our new research can help policymakers assess the trade-offs and make more informed decisions."

The findings, which will form the basis of a forthcoming book, paint a picture of an industry highly sensitive to legislative tinkering, where a policy designed to save consumer dollars in one market can quietly extinguish a clinical trial in another.

The Hidden Costs of Price Controls

Perhaps the most fiercely debated healthcare legislation of the decade is the U.S. Inflation Reduction Act (IRA). While celebrated for capping out-of-pocket costs for seniors, the Eira Initiative’s research highlights the law's chilling effect on specific types of medical research.

According to a working paper by Duane G. Schulthess and Harry P. Bowen, the enactment of the IRA has triggered a significant decline in research into secondary indications for small-molecule cancer medicines. The underlying economics explain why. Under the IRA, small-molecule drugs are subject to government price negotiations just nine years after their initial approval, compared to thirteen years for complex biologics.

In the realm of oncology, companies traditionally launch a drug for a narrow, late-stage patient population, then spend the next decade conducting trials to see if the same molecule works for earlier stages of the disease or entirely different tumor types. Because the IRA's nine-year clock begins at the first approval, the financial runway to recoup investments on those subsequent, secondary trials has been severely truncated.

Independent health economists have long warned of this exact scenario. While the law achieves its primary goal of reducing near-term drug spending, the data now suggests an invisible cost: the loss of follow-on discoveries that historically transformed single-use cancer drugs into versatile, multi-tumor treatments.

Europe’s Innovation Exodus

While the U.S. wrestles with the fallout of its new pricing paradigms, Europe is facing a full-blown innovation exodus. Research by Sandra Barbosu and Stephen Ezell documents a staggering transatlantic divergence: between 2020 and 2024, U.S.-originated medicines averaged 39 FDA approvals annually. European-originated medicines averaged just eight.

This nearly five-to-one disparity is not a reflection of European scientific capability, which remains world-class, but rather a symptom of structural and economic barriers. The Eira Initiative research points to the continent's fragmented, highly restrictive pricing policies. Navigating 27 distinct national health technology assessment (HTA) bodies—each demanding aggressive price concessions—has made Europe an increasingly hostile environment for capital-intensive drug launches.

Industry observers note that strict cost-containment frameworks have downstream effects on the broader financial ecosystem. European venture capital remains highly conservative compared to the aggressive, risk-tolerant funding environments in hubs like Boston or San Francisco. Consequently, promising European academic research is frequently licensed to U.S. firms or languishes in the "valley of death" between the laboratory and clinical trials. The result is a self-perpetuating cycle: lower expected returns due to price caps lead to lower venture capital investment, which in turn leads to longer delays in patient access to new medicines.

China’s Regulatory Acceleration

As Europe’s share of global drug origination shrinks, China is rapidly filling the void. A paper by Can Huang, Lina Lai, and Keyu Chen explores how Beijing’s strategic overhaul of its regulatory framework has transformed the country from a generic manufacturing hub into a formidable engine of novel drug development.

The turning point was a series of aggressive reforms by China's National Medical Products Administration (NMPA). By establishing priority review pathways, dramatically increasing regulatory staffing, and aligning its clinical standards with the International Council for Harmonisation (ICH), China effectively dismantled the bureaucratic bottlenecks that once delayed drug approvals by years. Furthermore, the NMPA's willingness to accept overseas clinical trial data has integrated China into the global R&D pipeline.

Coupled with a strengthening of intellectual property protections—including improved patent linkage systems and higher penalties for infringement—these regulatory efficiencies have unleashed a wave of domestic innovation. Chinese biopharmaceutical companies are no longer content to serve the domestic market; they are increasingly out-licensing novel molecules to Western giants and competing directly for global market share.

The Fragility of Rare Disease Pipelines

The Eira Initiative’s findings also underscore the extreme fragility of research targeting rare diseases. Because these conditions affect tiny patient populations, the traditional volume-based pharmaceutical business model collapses. Progress in this space is almost entirely dependent on targeted government incentives.

Research by Simona Gamba and Laura Magazzini demonstrates this vulnerability clearly. Their paper tracks a significant decline in orphan drug designations following recent reductions to the federal Orphan Drug Tax Credit in the United States.

Patient advocacy groups have consistently argued that these tax credits are not corporate loopholes, but essential lifelines that make the financing of non-blockbuster treatments viable. The data appears to validate this claim, showing that when the financial calculus of rare disease research is even slightly diminished by tax policy changes, capital quickly flees to safer, more lucrative therapeutic areas.

This dynamic extends to the broader global ecosystem. Another working paper by Alden Abbott and Satya Marar tackles the contentious issue of international cost-sharing, examining how trade agreements might compel other wealthy nations to shoulder a larger burden of R&D costs. As U.S. policymakers increasingly balk at subsidizing global innovation, the pressure is mounting to force foreign markets to adjust their pricing policies or risk stalling the development pipelines that the entire world relies upon.

Ultimately, the 18 working papers from the Eira Initiative serve as a stark reminder that the biopharmaceutical ecosystem operates as a highly interconnected global market. Capital is fluid, and innovation is entirely agnostic to geography. As governments continue to pull the levers of price controls, tax credits, and regulatory reform, they are not just managing healthcare budgets—they are actively deciding which diseases will see investment tomorrow, and which patients will be left waiting.